Dr. Jack West reviews the promise of combinations of immunotherapies for advanced NSCLC and the implications for the field of the initial report that the MYSTIC trial failed to show an improvement in progression-free survival with an IT combination.
Are Two Immunotherapy Agents Better than One? Will the MYSTIC Trial Prove to Be a Mistake? (BMIC-003)
